



Journal of Pharmaceutical and Biomedical Analysis Letters

CODEN (USA): JPBAC9 | ISSN: 2347-4742

Journal Home Page: www.pharmaresearchlibrary.com/jpbmal



RESEARCH ARTICLE

RP- HPLC Method Development and Validation for the Simultaneous Estimation of Donepezil and Memantine

S. Uday Venkata Sai Kumar*, G. Dharma Moorthy¹, N. Sujani², S. Veera Sekhar³, E. Vijay Kumar⁴

*Krishna Teja Pharmacy College, Tirupati, A.P., India

¹Associate Professor, Krishna Teja Pharmacy College, Tirupati, A.P., India

^{2,3,4}Assistant Professor, Srinivasa Institute of Pharmaceutical Sciences, Proddatur, A.P., India

ABSTRACT

A new method was established for simultaneous estimation of donepezil and memantine by RP-HPLC method. The chromatographic conditions were successfully developed for the separation of donepezil and memantine by using Xterra C18 5 μ m (4.6*250mm) column, flow rate was 1ml/min, mobile phase ratio was Phosphate buffer (0.05M) pH 4.6: ACN (55:45%v/v) (pH was adjusted with orthophosphoric acid), detection wave length was 255nm. The instrument used was WATERS HPLC Auto Sampler, Separation module 2695, PDA Detector 996, Empower-software version-2. The analytical method was validated according to ICH guidelines (ICH, Q2 (R1)). The linearity study for donepezil and memantine was found in concentration range of 1 μ g-5 μ g and 100 μ g-500 μ g and correlation coefficient (r^2) was found to be 0.999 and 0.999, % mean recovery was found to be 100% and 100.5%, %RSD for repeatability was 0.2 and 0.4, % RSD for intermediate precision was 0.5 and 0.1 respectively.

Keywords: Donepezil, Memantine, RP-HPLC, Phosphate buffer, CAN

ARTICLE INFO

Corresponding Author

S. Uday Venkata Sai Kumar

*Krishna Teja Pharmacy College,

Tirupati, A.P., India

MS-ID: JPBMAL4160



ARTICLE HISTORY: Received 03 Oct 2019, Accepted 31 Dec 2019, Available Online 18 January 2020

Copyright©2020 *Journal of Pharmaceutical and Biomedical Analysis Letters*. All rights reserved.

This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution and reproduction in any medium, provided the original work is properly cited.

Citation: S. Uday Venkata Sai Kumar, *et al*. RP- HPLC Method Development and Validation for the Simultaneous Estimation of Donepezil and Memantine. *J. Pharm, Biomed. A. Lett.*, 2020, 8(1): 11-16

CONTENTS

1. Introduction	12
2. Materials and Methods	12
3. Results and Discussion.	13
4. Conclusion.	15
5. References	15

1. Introduction

A drug is a substance which may have medicinal, intoxicating, performance enhancing or other effects when taken or put into a human body or the body of another animal and is not considered a food or exclusively a food. What is considered a drug rather than a food varies between cultures, and distinctions between drugs and foods and between kinds of drug are enshrined in laws which vary between jurisdictions and aim to restrict or prevent drug use. Even within a jurisdiction, however, the status of a substance may be uncertain or contested with respect to both whether it is a drug and how it should be classified if at all. There is no single, precise definition, as there are different meanings in drug control law, government regulations, medicine, and Colloquial usage. High performance liquid chromatography is a very sensitive analytical technique most widely used for quantitative and qualitative analysis of pharmaceuticals. The principle advantage of HPLC compared to classical column chromatography is improved resolution of the separated substance, faster separation times and the increased accuracy, precision and sensitivity.

Drug Profile:




Fig 1: Chemical Structure of Donepezil

Chemical Data:

IUPAC Name: (RS)-2-[(1-Benzyl-4-piperidyl) methyl]-5,6-dimethoxy-2,3-dihydroinden-1-one

Chemical formula : C₂₄H₂₉NO₃

Molecular weight : 379.492 g/mol

Category : anti-amnesic

Mechanism of action

Donepezil binds and inactivates reversibly the cholinesterases, thus inhibiting hydrolysis of acetylcholine. This results in increased acetylcholine concentrations at cholinergic synapses.




Fig 2: Chemical Structure of Memantine

Chemical Data:

IUPAC Name: 3,5-dimethyltricyclo[3.3.1.1^{3,7}]decan-1-amine or 3,5 dimethyladamantan-1-amine

Chemical Formula : C₁₂H₂₁N

Molecular weight : 179.3 g/mol

Category : noncompetitive NMDA receptor

antagonist

Mechanism of Action: Memantine acts as a non-competitive antagonist at different neuronal nicotinic acetylcholine receptors (nAChRs) at potencies possibly similar to the NMDA and 5-HT₃ receptors, but this is difficult to ascertain with accuracy because of the rapid desensitization of nAChR responses in these experiments. It can be noted that memantine is an antagonist at Alpha-7 nAChR, which may contribute to initial worsening of cognitive function during early memantine treatment.

Literature Review:

Rajgor VM et al., simple, accurate and specific RP-HPLC method has been developed and validated for the simultaneous estimation of Memantine HCl and Donepezil HCl in bulk and pharmaceutical dosage form.

Syeda Noorain Amena et al., To develop and validate stability indicating method for the analysis of Memantine HCl and Donepezil HCl.

U.K. Chhalotiya et al., A stability indicating HPLC method for the estimation of donepezil hydrochloride in tablets was developed and validated.

2. Materials and Methods

Method Development:

Method development for simultaneous estimation of Donepezil and Memantine in Pharmaceutical dosage forms includes the following steps:

1. Selection of Detection wavelength:

10 mg of Donepezil and Memantine was dissolved in mobile phase. The solution was scanned from 200-400 nm the spectrum was obtained. The overlay spectrum was used for selection of wavelength for Donepezil and Dihydro artemisinin. The isobestic point was taken as detection wavelength. The overlay spectrum is shown in Fig.1.




Fig 3: Over lay Spectrum of Donepezil and Memantine

Selection of column:

Column is selected based on solubility, polarity and chemical differences among Analytes [Column: Inertsil C18 (4.6 x 250mm, 5µm, Make: Waters)]

3. Selection of mobile phase:

- pH 3 phosphate buffer : Methanol (70 : 30% v/v)
- Buffer pH should be between 2 to 8.
- Below 2: siloxane linkages are cleaved.
- Above 8: dissolution of silica.
- pH selected: 3 ±0.05

- pH controls the elution properties by controlling the ionization characteristics.
- Reasons: To decrease the retention and improve separation. Good Response, Area, Tailing factor, Resolution.

Selection of flow rate:

Flow rate selected as 1ml/min

Flow rate is selected based on

1. Retention time
2. Column back pressure
3. Peak symmetry
4. Separation of impurities

Preparations and procedures:

Preparation of Phosphate buffer :(PH: 4.6): Weighed 6.8 grams of KH₂PO₄ was taken into a 1000ml beaker, dissolved and diluted to 1000ml with HPLC water, adjusted the pH to 4.6 with ortho phosphoric acid.

Preparation of mobile phase: A mixture of pH 4.6 Phosphate buffer 300 mL (30%), 700 mL of MEOH (70%) are taken and degassed in ultrasonic water bath for 5 minutes. Then this solution is filtered through 0.45 μ filter under vacuum filtration.

Diluent Preparation: Mobile phase is used as Diluent.

Preparation of the individual Donepezile standard preparation: 10mg of Donepezile working standard was accurately weighed and transferred into a 10ml clean dry volumetric flask and about 2ml of diluent is added. Then it is sonicated to dissolve it completely and made volume upto the mark with the diluent. (Stock solution). Further 10.0 ml from the above stock solution is pipette into a 100 ml volumetric flask and was diluted upto the mark with diluent.

Preparation of the individual Memantine standard preparation: 10mg of Memantine working standard was accurately weighed and transferred into a 10ml clean dry volumetric flask and about 2ml of diluent is added. Then it is sonicated to dissolve it completely and made volume upto the mark with the diluent (Stock solution). Further 1.0 ml from the above stock solution is pipette into a 10 ml volumetric flask and was diluted upto the mark with diluent.

Preparation of Sample Solution :(Tablet)

Accurately 10 tablets are weighed and crushed in mortar and pestle and weight equivalent to 10 mg of Memantine and Donepezile (marketed formulation) sample into a 10mL clean dry volumetric flask and about 7mL of Diluents is added and sonicated to dissolve it completely and made volume upto the mark with the same solvent. (Stock solution) Further 3 ml of above stock solution was pipetted into a 10ml volumetric flask and diluted upto the mark with diluent.

Procedure: 10μL of the standard, sample are injected into the chromatographic system and the areas for Memantine and Donepezile peaks are measured and the %Assay are calculated by using the formulae.

System Suitability:

Tailing factor for the peaks due to Memantine and Donepezile in Standard solution should not be more than 2.0. Theoretical plates for the Memantine and Donepezile peaks in Standard solution should not be less than 2000

Assay calculation:

$$\text{Assay \%} = \frac{\text{sample area}}{\text{Standard area}} \times \frac{\text{dilution sample}}{\text{dilution of standard}} \times \frac{P}{100} \times \frac{\text{Avg. wt}}{Lc} \times 100$$

Where,

P = Percentage purity of working standard

Lc = LABEL CLAIM OF drug in mg/ml

Optimized chromatogram is obtained by following conditions:

- Column : Symmetry C18 (4.6 x 150mm, 5μm, Make: XTerra)
- Buffer pH : 4.6
- Mobile phase : 70% MeOH : 30% Phosphate buffer pH-4.6
- Flow rate : 1 ml per min
- Wavelength : 273 nm
- Temperature : Ambient.
- Run time : 7 min.




Fig 3: Optimized chromatogram

Observation: From the above chromatogram it was observed that the Donepezile and Memantine peaks are well separated.

3. Results and Discussion

System Suitability: The system suitability of the method was checked by injecting five different preparations of the donepezile and memantine standard. The parameters of system suitability were checked.




Fig 4: Chromatogram for system suitability

Validation Parameters

Precision: Precision of the method was carried out for both sample and standard solutions as described under experimental work. The corresponding results are shown below.

Accuracy:

Sample solutions at different concentrations (50%, 100%, and 150%) were prepared and the % recovery was calculated.

Intermediate Precision (Ruggedness):

There was no significant change in assay content and system suitability parameters at different conditions of ruggedness like day to day and system to system variation.

Table 1: Results of system suitability parameters for donepezil and memantine

S. No	Name	Retention time(min)	Area (μ V sec)	Height (μ V)	USP resolution	USP tailing	USP plate count
1	Memantine	2.003	920101	116666		1.6	2711.8
2	Donepezil	5.067	552058	41531	11.0	1.3	3428.2

Table 2: Results of method precision for memantine

S. No	Sample area	Standard area	Percentage purity
1	983375	971536	101.04
2	985049	973007	101.03
3	982956	975717	100.54
4	985219	978909	100.44
5	994145	981422	101.09
Average			100.84
%RSD			0.304

Table 3: Results of method precision for donepezil

S. No	Sample area	Standard area	Percentage purity
1	592403	577531	101.36
2	592352	580381	101.85
3	592357	577723	102.32
4	592323	582190	101.44
5	596525	583378	101.09
Average			101.24
%RSD			0.46

Table 4: Results of Accuracy

Sample concentration	Sample set no	Sample area		Assay		% Recovery	
		ARTE	PIPE	ARTE	PIPE	ARTE	PIPE
50%	1	460064	276931	24.9	25.0	99.8	100
	2	460124	276694	24.6	24.9	99.6	99.6
	3	460216	276891	24.8	24.9	99.8	99.6
	Average Recovery						99.7%
100%	1	923429	554156	49.9	50.0	99.8	100
	2	923654	554897	49.8	49.9	99.6	99.8
	3	923742	556371	49.8	49.9	99.6	99.8
	Average recovery						99.6%
150%	1	1387901	828113	74.8	75.0	99.8	100
	2	1385360	828794	74.9	74.9	99.8	99.8
	3	1386984	828349	74.6	74.8	99.6	99.8
	Average recovery						99.7%

Acceptance criteria: The percentage recovery at each level should be between (97-103%). The results obtained for recovery at 50%, 100%, 150% are within the limits. Hence the method is accurate.

Table 5: Results of Intermediate precision for Memantine

S. No	Sample area	Standard area	Percentage purity
1	979556	984395	99.30
2	982467	984039	99.64
3	979717	983976	99.36
4	978909	984278	99.28
5	981432	973915	100.57
Average			99.63
%RSD			0.54

Table 6: Results of Intermediate precision for Donepezile

S. No	Sample area	Standard area	Percentage purity
1	583416	593403	99.12
2	583657	594352	99.01
3	584731	593357	99.52
4	583594	592673	99.61
5	597649	593671	99.12
Average			99.27
%RSD			0.27

Acceptance criteria: %RSD of five different sample solutions should not be more than 2. The %RSD obtained is within the limit, hence the method is rugged.

4. Conclusion

On the basis of experimental results, the proposed method is suitable for the quantitative determination of memantin and donepezil in pharmaceutical dosage form. The method provides great sensitivity, adequate linearity and repeatability. The estimation of Memantin and Donepezil was done by RP-HPLC. The Phosphate buffer was pH 4.6 and the mobile phase was optimized which consists of MeOH : Phosphate buffer mixed in the ratio of 70:30 % v/v. A Symmetry C18 (4.6 x 150mm, 5 μ m, Make XTerra) column used as stationary phase. The detection was carried out using UV detector at 273 nm. The solutions were chromatographed at a constant flow rate of 1.0 ml/min. the linearity range of Memantin and donepezil were found to be from 25-125 μ g/ml. Linear regression coefficient was not more than 0.999. The values of % RSD are less than 2% indicating accuracy and precision of the method. The percentage recovery varies from 97-102% of Memantin and donepezil LOD and LOQ was found to be within limit. The proposed method is precise, simple and accurate to determine the amount of Memantin and donepezil in formulation. High percentage of recovery shows that the method is free from the interference of excipients used in the formulation. So the method can be useful in the routine quality control of these drugs.

5. References

- [1] G.R. Chatwal, S.K. Anand, Text book of Instrumental Methods of Chemicals Analysis, Himalaya Publishing House, 5th Ed, 2002, p.2.566-2.570.
- [2] G.W.Ewing, Text book of Instrumental Methods of Chemical Analysis, Mc Graw-Hill Book Company, 5th Ed, p.375-385.
- [3] B.K. Sharma, Textbook of Instrumental Methods of Chemical Analysis, GOEL publishing house, Meerut, 23rd Ed, p.288-289.
- [4] G.Vidyasagar, Textbook of Instrumental Methods of Drug Analysis, Pharmamed Press, 2009, p.106-120.
- [5] H. H Willard, L. L Merritt, J. A Dean, and F. A Settle, Textbook of Instrumental Methods of Analysis, CBS publishers and distributors, New Delhi, 7th Ed, 1986, p.592-596.
- [6] H.H.Tackett, J.A.Cripe, G.Dyson, Positive displacement reciprocating pump fundamentals-power and direct acting types, Proceedings of the twenty-fourth international pump user's symposium, 2008, p.45-58.
- [7] D.A.Skoog, F.J.Holler, S.R.Crouch, Textbook of Instrumental Analysis, Brooks/Cole, Cengage Learning India Private Limited, 2007, p.900-906.
- [8] R. E. Schirmer, Textbook of Modern Methods of Pharmaceuticals, CRC press, 2nd Ed, P.242-244.
- [9] LR.Snyder, JJ Kirkland, LG.Joseph, Practical HPLC Method Development, Wiley Inter Science, New York, 2nd Ed, 1997, p. 1-56.
- [10] Ranjith singh, HPLC Method Development and Validation- an Overview, J Pharm. Educ. Res.4 (2013) 26-33.
- [11] ICH: Q2B, Analytical Validation – Methodology (1996)
- [12] A.SUNEETHA et al, A Validated Rp Hplc Method for Simultaneous Estimation of Darunavir in Combined Dosage Form. International Journal of Pharmacy and Pharmaceutical Sciences. Vol 3, Issue 1, 2011.
- [13] Putchakayala Purnachandra Rao et al, Simple and Sensitive Analytical Method Development and Validation of Tenofovir disoproxil fumarate, Cobicistat, Elvitegravir Bulk Drug by Rp-Hplc. Der Pharma Chemica, 2011, 3 (6):494-499.
- [14] Nageswara Rao R, Simple And Sensitive Analytical Method Development and Validation Of cobicistat Bulk Drug By Rp-Hplc. Der Pharma Chemica 01/2011; 3(6):494-499.
- [15] T. T. Mariappan et al, Analytical Method Development And Validation For Simultaneous Estimation Of darunavir And cobicistat By Rp-Hplc. International Journal of Research and Development in Pharmacy and Life Sciences. 1996.3(4);432-524
- [16] Ponnilarasan et al, Rp -- Hplc Method For Simultaneous Estimation Of Antiretroviral Drugs Lopinavir And Ritonavir In Tablet Dosage Form. Digest Journal of Nanomaterials & Biostructures (DJNB); Jul 2010, Vol. 5 Issue 3, p771.
- [17] S. Mohan Varma. Development and Validation of a RP-HPLC Method for Determination of Lopinavir In Bulk And Pharmaceutical Dosage Form. International Journal of Research in Pharmacy and Chemistry. Vol. 4 Issue 3, p669, 2002

- [18] P. Nagaraju *et al*, Development and Validation of Reverse Phase HPLC Method for the Simultaneous Estimation of Lopinavir and Ritonavir in Pharmaceutical Dosage Forms. *International Journal of Research in Pharmaceutical and Biomedical Sciences*. 2001;28(1):192–197.
- [19] K. Gowtham *et al*, Sensitive Analytical Method Development and Validation of Ritonavir Bulk drugs by RP-HPLC. *Journal of Scientific Research in Pharmacy*. 2013;2(1):125-127
- [20] 20. Anusha Tiyyagura *et al*, Method Development And Validation For The Simultaneous Estimation Of Atazanavir And Ritonavir In Pharmaceutical Dosage Form By Rp-Hplc, *IJCBS* 2012, 3(1), 44-54. ISSN: 2249-9504.